Metabolic syndrome in adult-onset latent autoimmune diabetes

Metabolic Syndrome and Related Disorders

Volumn 3, Issue 2, 2005, Pages 174-180

  Li, Xia ^a   Zhou, Zhi Guang ^a   Huang, Gan ^a   Su, Heng ^a   Yan, Xiang ^a   Yang, Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULIN SENSITIZING AGENT;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELL LOSS; CONTROLLED STUDY; DYSLIPIDEMIA; HUMAN; HYPERTENSION; IMMUNOASSAY; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN RESISTANCE; LATENT AUTOIMMUNE DIABETES IN ADULTS; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TURBIDIMETRY;

EID: 24644462796     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2005.3.174     Document Type: Article

References (22)

1. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-362.
2. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303.
3. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization, 1999.
4. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of adults): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-1467.
5. Carlsson A, Sundkvist G, Groop L, Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 2000;85:76-78.
6. Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL. Insulin resistance in latent autoimmune diabetes of adulthood. Ann NY Acad Sci 2003;1005:374-377.
7. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
8. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med 2001;250:105-120.
9. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute, 2001 (NIH pub. no. 01-3670).
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
11. Petersen JS, Hejnaes KR, Moody A, Karlsen AE, Marshall MO, Hoier-Madsen M, Boel E, Michelsen BK, Dyrberg T. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994;43:459-467.
12. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, Karlsen AE, Boel E, Michelsen B, Lernmark A. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994;37:344-350.
13. Jia WP, Lu JX, Xiang KS, Bao YQ, Lu HJ, Chen L. Prediction of abdominal visceral obesity from body mass index, waist circumference and waist-hip ratio in Chinese adults: receiver operating characteristic curve analysis. Biomed Environ Sci 2003;16:206-211.
14. Kriketos AD, Greenfield JR, Peake PW, Furler SM, Denyer GS, Charlesworth JA, Campbell LV. Inflammation, insulin resistance, and adiposity. A study of first-degree relatives of type 2 diabetic subjects. Diabetes Care 2004;27:2033-2040.
15. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003;4: 487-492.
16. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192-200.
17. Lee ZS, Critchley JA, Ko GT, Anderson PJ, Thomas GN, Young RP, Chan TY, Cockram CS, Tomlinson B, Chan JC. Obesity and cardiovascular risk factors in Hong Kong Chinese. Obes Rev 2002;3:173-182.
18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
19. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001;44:914-922.
20. Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003;26:2865-2870.
21. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-1405.
22. Barnett AH. Insulin-sensitizing agents - thiazolidinediones (glitazones). Curr Med Res Opin 2002;18: S31-S39.